Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Not Applicable

Not yet recruiting

• Conditions: Hepatocellular Carcinoma (HCC)
• Interventions: Drug: Ipilimumab and Nivolumab; Radiation: Stereotactic Body Radiotherapy (SBRT)

• Registration Number: NCT07075120
• Lead Sponsor: University of Hawaii

Brief Summary

Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii. This disparity is influenced by factors such as higher prevalence of chronic hepatitis B, non-alcoholic fatty liver disease, limited access to early detection, and delayed diagnoses. NHPI patients are also underrepresented in clinical trials, limiting the relevance of treatment advances for this population.

The standard treatment for HCC is surgical resection; however, many NHPI patients present with unresectable disease. Recent advances with immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, have shown promise in treating advanced HCC and improving survival in previously untreatable cases. Additionally, stereotactic body radiotherapy (SBRT) has been shown to enhance survival and local control when combined with systemic therapies like ICIs. However, without surgery, outcomes remain suboptimal, with response rates for ICIs alone at 20-30%, and combination ICI-SBRT treatment showing slightly better results but still a high risk of progression.

Despite improvements in HCC treatment, significant gaps remain in managing borderline resectable disease, especially in NHPI patients. This study aims to evaluate the safety and efficacy of combining ICIs and SBRT with curative surgery for patients with borderline resectable HCC, focusing on NHPI populations. The study will also explore the use of biomarkers such as cell-free DNA (cfDNA), CD8+ T-cell infiltration, and serum cytokine markers to guide personalized treatment strategies. Preliminary findings suggest that this multimodal approach may improve outcomes and enable surgical resection for patients previously considered inoperable.

This study seeks to address the unmet need for effective treatment strategies in borderline resectable HCC and to improve survival outcomes for underserved NHPI populations.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-20
• Study First Submitted QC: 2025-07-10
• Last Update Submitted: 2025-07-10
• Study First Posted: 2025-07-20
• Last Update Posted: 2025-07-20
• Study Start: 2025-08-01
• Primary Completion: 2027-08-01
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Histologically or cytologically confirmed hepatocellular cancer

  • Locally advanced/borderline resectable HCC as defined by:

    • Solitary tumor >5 cm, OR
    • Unilobar multifocal disease either with >3 tumors or one tumor >3 cm, OR
    • Bilobar disease with adequate future liver remnant, still technically resectable, OR
    • High risk disease features (tumor >3 cm with macrovascular invasion or tumor >3 cm with AFP>400).

  • No extrahepatic spread, no nodal disease, no bilateral left and right branch portal vein involvement, no hepatic vein / IVC involvement. Unilateral hepatic vein involvement is not exclusionary.

  • Measurable disease per RECIST 1.1 as determined by the investigator

  • Age ≥ 18 years old on the day of consent

  • ECOG performance status ≤1 (Appendix XX)

  • Adequate organ and marrow function, as defined below. Criteria "a," "b," "c," and "f" cannot be met with transfusions, infusions, or growth factor support administered within 14 days of starting the first dose.

    • Hemoglobin ≥9 g/dL
    • Absolute neutrophil count ≥1000/μL
    • Platelet count ≥90,000/μL
    • Total bilirubin (TBL) <2.0 mg/dL
    • ASTandALT≤5×ULN
    • Albumin≥2.8g/dL
    • International normalized ratio(INR)≤2xULN
    • Calculated creatinine clearance ≥ 40 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance

Exclusion Criteria

• Prior systemic therapy for hepatocellular carcinoma

  • Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of study drug(s).

  • Ascites that requires ongoing paracentesis, within 6 weeks prior to the first scheduled dose, to control symptoms.

  • Active or prior documented GI variceal bleed or history of upper GI bleeding, ulcers, or esophageal varices with bleeding within 60 days prior to registration; adequate endoscopic therapy according to institutional standards is required for patients with history of esophageal variceal bleeding or assessed as high risk for esophageal variceal by the treating investigator.

  • Hepatic encephalopathy within 12 months of trial registration

  • Patient currently exhibits symptomatic or uncontrolled hypertension defined as diastolic blood pressure >90 mmHg or systolic blood pressure >140 mmHg.

  • Prior external beam radiation therapy to the liver, prior yttrium-90 radioembolization

  • HBV viral load >100 IU/mL, ongoing corticosteroid therapy >10 mg prednisone daily, and active autoimmune disease requiring systemic therapy in the past 2 years.

  • Direct tumor extension into stomach, duodenum, small or large bowel

  • Active or untreated central nervous system (CNS) and leptomeningeal metastases

  • History of another primary malignancy except for:

    • Malignancy treated with curative intentand with no known active disease ≥ 5years before the first dose of study drug(s) and of low potential risk for recurrence
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

  • Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), or human immunodeficiency virus (positive human HIV 1/2 antibodies).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ipilimumab and Nivolumab with SBRT and Surgical Resection	Ipilimumab and Nivolumab	Arm A: Patients receive ipilimumab 3mg/kg and nivolumab 1mg/kg for nine weeks (three cycles). Following completion of preoperative immunotherapy, imaging with CT or MRI is performed to determine resectability. Eligible patients proceed to surgical resection. Arm B: Patients who are not eligible for resection continue immunotherapy (ipilimumab and nivolumab) for one additional cycle, then nivolumab 480mg every four weeks combined with stereotactic body radiotherapy (SBRT). SBRT is administered in 3-5 fractions, and patients continue imaging every nine weeks. Surgical resection is performed once resectability is confirmed.
Ipilimumab and Nivolumab with SBRT and Surgical Resection	Stereotactic Body Radiotherapy (SBRT)	Arm A: Patients receive ipilimumab 3mg/kg and nivolumab 1mg/kg for nine weeks (three cycles). Following completion of preoperative immunotherapy, imaging with CT or MRI is performed to determine resectability. Eligible patients proceed to surgical resection. Arm B: Patients who are not eligible for resection continue immunotherapy (ipilimumab and nivolumab) for one additional cycle, then nivolumab 480mg every four weeks combined with stereotactic body radiotherapy (SBRT). SBRT is administered in 3-5 fractions, and patients continue imaging every nine weeks. Surgical resection is performed once resectability is confirmed.

Primary Outcome Measures

Name	Time	Method
Feasibility of Treatment Regimen	From treatment initiation to surgery completion (up to 12 months)	Feasibility will be defined as fewer than 5 failures of resection due to treatment-related factors (e.g., toxicity, delay in treatment).; (Co-primary endpoint; this outcome assesses the tolerability and logistical feasibility of the neoadjuvant treatment strategy.) Unit of Measure: Number of failures (count)
R0 Resection Rate	From treatment initiation to surgery (up to 12 weeks)	The proportion of patients achieving R0 surgical resection, defined as complete resection with negative margins.; (Co-primary endpoint; this outcome reflects the treatment's impact on surgical resectability.) Unit of Measure: Percentage of participants

Secondary Outcome Measures

Name	Time	Method
Pathologic Complete Response (pCR) and Disease-Free Survival (DFS)	From the date of treatment initiation until disease recurrence or progression, assessed up to 36 months.	pCR and DFS will be evaluated as secondary endpoints.
Toxicity Evaluation	From the start of treatment to the time of surgery, assessed up to 12 months.	Toxicity will be evaluated using the CTCAE v6.0 grading system for grade 3-4 adverse events prior to surgery.
Overall Survival (OS)	From the date of treatment initiation until death, assessed up to 36 months.	OS will be estimated from the date of treatment initiation to the date of death.
Objective Response Rate (ORR)	From the date of treatment initiation until the date of best documented response, assessed up to 36 months.	ORR will be assessed based on RECIST v1.1 criteria.

Trial Locations

Locations (1)

University of Hawai'i Cancer Center; 🇺🇸 Honolulu, Hawaii, United States